R&D technology investments: misguided and expensive or a better way to discover medicines?

Strategic Management Group, Sandwich Laboratories, Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ, UK.
Drug Discovery Today (Impact Factor: 6.69). 10/2006; 11(17-18):775-84. DOI: 10.1016/j.drudis.2006.07.007
Source: PubMed


The pharmaceutical industry is in crisis owing to spiralling costs and a lack of new product launches. It is said that expensive investments in technology have not paid off. But is this really true? In this review, we explore some of the recent medicines that were, or are being, brought to market, and we discuss how they were discovered and what difference new technologies have made during the discovery of these medicines.

1 Read
  • Source
    • "The process of chemical drug discovery is long and arduous that it begins from the search of a potential candidate to the development of a marketable drug. It can span the course of more than a decade, and can cost an average of 800 million USD in the USA [1] [2] [3]. Under special circumstances such as the search for effective drugs to treat AIDS, the Food and Drug Administration (FDA) in USA and other countries have encouraged an abbreviated process for drug testing and approval (called fast tracking) [4] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Synthetic chemical drugs, while being efficacious in the clinical management of many diseases, are often associated with undesirable side effects in patients. It is now clear that the need of therapeutic intervention in many clinical conditions cannot be satisfactorily met by synthetic chemical drugs. Since the research and development of new chemical drugs remain time-consuming, capital-intensive and risky, much effort has been put in the search for alternative routes for drug discovery in China. This narrative review illustrates various approaches to the research and drug discovery in Chinese herbal medicine. Although this article focuses on Chinese traditional drugs, it is also conducive to the development of other traditional remedies and innovative drug discovery.
    Evidence-based Complementary and Alternative Medicine 03/2011; 2011(1):403709. DOI:10.1093/ecam/neq056 · 1.88 Impact Factor
  • Source
    • "Advances in knowledge and technology have greatly increased our expectations of improved healthcare. The investment into Research and Development (R&D) of new medicines has seen spectacular growth over the past decade, but despite technical progress in drug discovery technologies, there has not been a concomitant increase in R&D productivity [13]. The current developments in the basic discovery sciences have not been mirrored by simultaneous progress in understanding the molecular bases of disease. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The dominant conceptual reductionism in drug discovery has resulted in many promising drug candidates to fail during the last clinical phases, mainly due to a lack of knowledge about the patho-physiological pathways they are acting on. Consequently, to increase the revenues of the drug discovery process, we need to improve our understanding of the molecular mechanisms underlying complex cellular processes and consider each potential drug target in its full biological context. Here, we review several strategies that combine computational and experimental techniques, and suggest a systems pathology approach that will ultimately lead to a better comprehension of the molecular bases of disease.
    FEBS Letters 05/2008; 582(8):1259-65. DOI:10.1016/j.febslet.2008.02.014 · 3.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug development is a complex, lengthy and expensive process. Pharmaceutical companies and regulatory authorities have recognised that the drug development process needs optimisation for efficiency in view of the return on investments. Pharmacokinetics and pharmacodynamics are the two main principles determining the relationship between dose and response. This article provides an update on integrated approaches towards drug development by linking pharmacokinetics, pharmacodynamics and disease aspects into mathematical models. Gradually, a transition is taking place from a rather empirical approach towards a modelling- and simulation-based approach to drug development. The main learning phases should be phases 0, I and II, whereas phase III studies should merely have a confirmatory purpose. In model-based drug development, mechanism-based mathematical models, which are iteratively refined along the path of development, incorporate the accumulating knowledge of the investigational drug, the disease and their mutual interference in different subsets of the target population. These models facilitate the design of the next study and improve the probability of achieving the projected efficacy and safety endpoints. In this article, several theoretical and practical aspects of an integrated approach towards drug development are discussed, together with some case studies from different therapeutic areas illustrating the application of pharmacokinetic/pharmacodynamic disease models at different stages of drug development.
    Clinical Pharmacokinetics 02/2007; 46(9):713-37. DOI:10.2165/00003088-200746090-00001 · 5.05 Impact Factor
Show more